April 3 (Reuters) - Pharmacy benefit managers OptumRx

and Express Scripts have asked the federal judge overseeing

nationwide litigation over the opioid crisis to recuse himself

from cases against them, claiming that the judge has had

frequent backchannel communication with a plaintiffs' attorney.

In a motion filed in Cleveland, Ohio federal court, the PBMs

cited reports that Michael Kahn, a Florida lawyer representing

some of the cities and counties suing the companies, had

repeatedly told potential clients that Peter Weinberger, a

leading plaintiffs' attorney in the litigation, spoke to U.S.

District Judge Dan Aaron Polster "every day" and got "inside

information" from him.

Kahn also claimed that Polster was a "tremendous

plaintiff-oriented judge" who put "enormous pressure" on

defendants to settle, according to the PMBs.

A spokesperson for the plaintiffs' attorneys declined to

comment. Helen Norton, an assistant to Polster, said the judge

could not comment on a pending case.

Optum and Express Scripts told Polster in February about

Kahn's statements, which they discovered by reviewing public

records, and sought disclosure of all communications between

plaintiffs' counsel and the judge outside defense counsel's

presence.

Polster did not grant that request but ordered an

evidentiary hearing at which Kahn was questioned last month.

Kahn testified that he "misspoke" and had never been told that

Weinberger engaged in frequent conversations with the judge.

Polster sanctioned Kahn with a fine of $100,000, finding

that his statements were "without any factual basis" and

"improperly cast aspersions upon the integrity of the court."

The PBMs, however, said that Polster's response, and refusal

to disclose the communications they requested, were reason for

him to recuse himself.

"There is no question that Mr. Kahn's statements have

undermined the integrity" of the litigation, the PBMs wrote.

"But the response to Mr. Kahn's statements has only further

undermined the appearance of impartiality."

The opioid litigation, which includes thousands of lawsuits

brought by local governments across the country, has already

resulted in more than $50 billion in settlements resolving

claims that drug manufacturers concealed the addictive pain

drugs' risks, and that distributors and pharmacies ignored red

flags that pills were being diverted into illegal channels.

Less attention has been paid so far to the claims against

PBMs like UnitedHealth Group's ( UNH ) Optum and Cigna Group's

Express Scripts. PBMs act as middlemen between drug

companies, health plans and pharmacies to negotiate prescription

drug prices and decide which drugs will be covered by insurance.

The parent companies are also named as defendants in the case.

Plaintiffs allege that PBMs both colluded with drugmakers to

promote dangerous drugs and failed to limit access to them in

response to red flags. The cases against PBMs are still in early

stages, with pretrial motions expected to continue into 2026.

Optum and Express Scripts have said that all the claims

against them are without merit.

The PBMs in 2023 had sought, unsuccessfully, to get a

special master removed from the case after being inadvertently

copied on an email that they said showed he was biased.

The MDL is In Re: National Prescription Opiate Litigation,

U.S. District Court for the Northern District of Ohio, No.

1:17-md-02804.

For plaintiffs: Jayne Conroy of Simmons Hanly Conroy; Joe

Rice of Motley Rice; Paul Farrell of Farrell & Fuller; and Peter

Weinberger of Spangenberg Shibley & Liber

For OptumRx: Brian Boone of Alston & Bird

For Express Scripts: Jonathan Cooper of Quinn Emanuel

Urquhart & Sullivan

Read more:

Optum, Express Scripts want opioid special master out after

reply-all email mishap

Purdue Pharma, Sacklers reach $7.4 billion national opioid

settlement

(Reporting By Brendan Pierson in New York)